
    
      Eligibility criteria

        1. Osteosarcoma which has relapsed after treatment and for which no second line
           chemotherapy is planned and in which disease is not amenable to surgery.

        2. Patient should be able to follow-up 3 monthly for clinical and imaging assessment as
           well as biochemical tests
    
  